PADI4 and hypertrophic cardiomyopathy: Inhibition of protein arginine deiminase 4 (PAD4), with an orally available inhibitor (JBI-589), prevents the development of hypertrophic cardiomyopathy and diastolic heart failure in murine inflammatory arthritis with reduced neutrophil infiltration, NET deposition, and biomarkers of thromboinflammation in the myocardium.